Triptorelin Pamoate
(ZBVJFYPGLGEMIN-OYLNGHKZSA-N)
Structure
- SMILES
- OC(=O)c1cc2ccccc2c(c1O)Cc1c(O)c(cc2c1cccc2)C(=O)O.OC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)NCC(=O)N)CCCN=C(N)N)CC(C)C)Cc1c[nH]c2c1cccc2)Cc1ccc(cc1)O)NC(=O)[C@H](Cc1c[nH]c2c1cccc2)NC(=O)[C@@H](NC(=O)[C@@H]1CCC(=O)N1)Cc1[nH]cnc1
- Molecular Formula:
- C87H98N18O19
- Molecular Weight:
- 1699.820
- Log P:
- 7.5914
- Hydrogen Bond Acceptor:
- 34
- Hydrogen Bond Donor:
- 21
- TPSA:
- 605.48
- CAS Number(s):
- 57773-63-4; 124508-66-3
Synonym(s)
1.
Triptorelin Pamoate
2.
D-Trp-6-LH-RH
3.
LHRH, Trp(6)-
4.
Triptorelin
5.
6-D-Tryptophan-Luteinizing Hormone-Releasing Factor (Pig)
6.
AY-25650
7.
CL-118532
8.
Decapeptyl
9.
Decapeptyl Depot
10.
Decapeptyl LP
11.
Decapeptyl Trimestral
12.
GnRH, Trp(6)-
13.
LHRH, Tryptophyl(6)-
14.
Trelstar
15.
Triptorelin Embonate
16.
Wy-42462
17.
AY 25650
18.
AY25650
19.
CL 118532
20.
CL118532
21.
Embonate, Triptorelin
22.
Pamoate, Triptorelin
23.
Trimestral, Decapeptyl
24.
Wy 42462
25.
Wy42462
External Link(s)
| MeSH | D017329 |
| PubChem Compound | 25074469 |
| CHEMBL | CHEMBL1200554 |
| KEGG | dr:D06248 |
Adverse Drug Event(s)
| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | Abdominal Pain | FAERS: 6 | US FAERS | |
| 2 | Headache | FAERS: 5 | US FAERS | |
| 3 | Vomiting | FAERS: 5 | US FAERS | |
| 4 | Diplopia | FAERS: 4 | US FAERS | |
| 5 | Nausea | FAERS: 4 | US FAERS | |
| 6 | Angioedema | FAERS: 3 | US FAERS | |
| 7 | Asthenia | FAERS: 3 | US FAERS | |
| 8 | Cardiovascular insufficiency | FAERS: 3 | US FAERS | |
| 9 | Injection site pain | FAERS: 3 | US FAERS | |
| 10 | Metrorrhagia | FAERS: 3 | 10763848 | CTD US FAERS |
| 11 | Ovarian Hyperstimulation Syndrome | FAERS: 3 | US FAERS | |
| 12 | Thrombocytopenia | FAERS: 3 | US FAERS | |
| 13 | Drug exposure during pregnancy | FAERS: 2 | US FAERS | |
| 14 | Endometrial disorder | FAERS: 2 | US FAERS | |
| 15 | Fatigue | FAERS: 2 | US FAERS | |
| 16 | Granuloma | FAERS: 2 | US FAERS | |
| 17 | Hepatitis | FAERS: 2 | US FAERS | |
| 18 | Lymphocytic infiltration | FAERS: 2 | US FAERS | |
| 19 | Pain | FAERS: 2 | US FAERS | |
| 20 | Pancreatitis | FAERS: 2 | US FAERS | |
| 21 | Syncope | FAERS: 2 | US FAERS | |
| 22 | Urticaria | FAERS: 2 | US FAERS | |
| 23 | Anaphylactic shock | FAERS: 1 | US FAERS | |
| 24 | Anxiety | FAERS: 1 | US FAERS | |
| 25 | Aphthous Stomatitis | FAERS: 1 | US FAERS | |
| 26 | Arthralgia | FAERS: 1 | US FAERS | |
| 27 | Arthritis | FAERS: 1 | US FAERS | |
| 28 | Ascites | FAERS: 1 | US FAERS | |
| 29 | Autoimmune hepatitis | FAERS: 1 | US FAERS | |
| 30 | Blood creatine phosphokinase increased | FAERS: 1 | US FAERS | |
| 31 | Blood testosterone increased | FAERS: 1 | US FAERS | |
| 32 | Bone Sarcoma | FAERS: 1 | US FAERS | |
| 33 | Capillary Leak Syndrome | FAERS: 1 | US FAERS | |
| 34 | Chills | FAERS: 1 | US FAERS | |
| 35 | Cholecystitis | FAERS: 1 | US FAERS | |
| 36 | Complex partial seizures | FAERS: 1 | US FAERS | |
| 37 | Cytolytic hepatitis | FAERS: 1 | US FAERS | |
| 38 | Drug administration error | FAERS: 1 | US FAERS | |
| 39 | Ecchymosis | FAERS: 1 | US FAERS | |
| 40 | Electrolyte imbalance | FAERS: 1 | US FAERS | |
| 41 | Emotional disorder | FAERS: 1 | US FAERS | |
| 42 | Fibromyalgia | FAERS: 1 | US FAERS | |
| 43 | Fluid imbalance | FAERS: 1 | US FAERS | |
| 44 | Flushing | FAERS: 1 | US FAERS | |
| 45 | General physical condition abnormal | FAERS: 1 | US FAERS | |
| 46 | Hydrocephalus | FAERS: 1 | US FAERS | |
| 47 | Hypersensitivity | FAERS: 1 | US FAERS | |
| 48 | Hypertensive crisis | FAERS: 1 | US FAERS | |
| 49 | Hypotension | FAERS: 1 | US FAERS | |
| 50 | Infection | FAERS: 1 | US FAERS | |
| 51 | Injection site abscess | FAERS: 1 | US FAERS | |
| 52 | Labile hypertension | FAERS: 1 | US FAERS | |
| 53 | Leukopenia | FAERS: 1 | US FAERS | |
| 54 | Lymphadenopathy | FAERS: 1 | US FAERS | |
| 55 | Malaise | FAERS: 1 | US FAERS | |
| 56 | Medication Error | FAERS: 1 | US FAERS | |
| 57 | Multiple Sclerosis | FAERS: 1 | US FAERS | |
| 58 | Musculoskeletal Pain | FAERS: 1 | US FAERS | |
| 59 | Myalgia | FAERS: 1 | US FAERS | |
| 60 | Myocarditis | FAERS: 1 | US FAERS | |
| 61 | Neutropenia | FAERS: 1 | US FAERS | |
| 62 | Ophthalmoplegia | FAERS: 1 | US FAERS | |
| 63 | Optic Neuritis | FAERS: 1 | US FAERS | |
| 64 | Ovarian enlargement | FAERS: 1 | US FAERS | |
| 65 | Overdose | FAERS: 1 | US FAERS | |
| 66 | Pelvic fluid collection | FAERS: 1 | US FAERS | |
| 67 | Petechiae | FAERS: 1 | US FAERS | |
| 68 | Photophobia | FAERS: 1 | US FAERS | |
| 69 | Pneumothorax | FAERS: 1 | US FAERS | |
| 70 | Product measured potency issue | FAERS: 1 | US FAERS | |
| 71 | Pruritus | FAERS: 1 | US FAERS | |
| 72 | Rheumatoid Arthritis | FAERS: 1 | US FAERS | |
| 73 | Sinus bradycardia | FAERS: 1 | US FAERS | |
| 74 | Skin reaction | FAERS: 1 | US FAERS | |
| 75 | Subcutaneous Abscess | FAERS: 1 | US FAERS | |
| 76 | Swelling | FAERS: 1 | US FAERS | |
| 77 | Therapy non-responder | FAERS: 1 | US FAERS | |
| 78 | Thrombosis | FAERS: 1 | US FAERS | |
| 79 | Vasculitis | FAERS: 1 | US FAERS | |
| 80 | Vertigo | FAERS: 1 | US FAERS | |
| 81 | Visual disturbance | FAERS: 1 | US FAERS | |
| 82 | jaundice | FAERS: 1 | US FAERS | |
| 83 | Adenocarcinoma | 10763848 | CTD | |
| 84 | Drug ineffective | Canada Vigilance: 2 | Canada Vigilance | |
| 85 | Hyperprolactinemia | 2954994 3158510 | CTD | |
| 86 | Hypogonadism | 15640438 20463352 | CTD | |
| 87 | Injury associated with device | Canada Vigilance: 1 | Canada Vigilance | |
| 88 | Needle issue | Canada Vigilance: 1 | Canada Vigilance | |
| 89 | Syringe issue | Canada Vigilance: 3 | Canada Vigilance | |
| 90 | Uterine Neoplasms | 10763848 | CTD | |
| 91 | Wrong technique in product usage process | Canada Vigilance: 2 | Canada Vigilance |
Powered by :
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120236
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.